Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in
Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. Under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primar...
Daiichi Sankyo Company, Limited announced that a Board of Directors Meeting resolved that American Regent, Inc. and PharmaForce, Inc., subsidiaries of Luitpold Pharmaceuticals, Inc. are to undergo an absorption-type merger with Luitpold as the surviving company. The name of said surviving company, ...
Corporate Video For people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges. ...
Corporate Video For people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges. ...
Japanese pharma concern Daiichi Sankyo is acquiring privately-held German biotech firm U3 Pharma for 150m [euro].(Business Digest)(concern Daiichi Sankyo acquired with U3 Pharma )(Brief article)Eisberg, Neil
Category: Daiichi Sankyo 01 November 2011 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has established a new Japanese vaccine research unit to be located in its Kasai R&D Center (Edogawa-ku, Tokyo). Daiichi Sankyo has been strengthening and expanding ...
Daiichi Sankyo has positioned itself into a global pharma innovator several years ago and focus on an innovation in oncology. It keeps sustainable innovation and maintain leading positions in the pharmaceutical area. It has outstanding products to provide sufficient cash flow and keeps investing them ...
Daiichi Sankyo Company, Limited announced that it has launched Delytact (teserpaturev/G47?), an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo. ...
Daiichi Sankyo Company, Limited announced that it has launched Delytact (teserpaturev/G47?), an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo. ...